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ABSTRACT
The EULAR Sjögren’s syndrome (SS) disease activity
index (ESSDAI) is a systemic disease activity index that
was designed to measure disease activity in patients with
primary SS. With the growing use of the ESSDAI, some
domains appear to be more challenging to rate than
others. The ESSDAI is now in use as a gold standard to
measure disease activity in clinical studies, and as an
outcome measure, even a primary outcome measure, in
current randomised clinical trials. Therefore, ensuring an
accurate and reproducible rating of each domain, by
providing a more detailed definition of each domain, has
emerged as an urgent need. The purpose of the present
article is to provide a user guide for the ESSDAI. This
guide provides definitions and precisions on the rating of
each domain. It also includes some minor improvement
of the score to integrate advance in knowledge of disease
manifestations. This user guide may help clinicians to
use the ESSDAI, and increase the reliability of rating and
consequently of the ability to detect true changes over
time. This better appraisal of ESSDAI items, along with
the recent definition of disease activity levels and minimal
clinically important change, will improve the assessment
of patients with primary SS and facilitate the
demonstration of effectiveness of treatment for patients
with primary SS.
INTRODUCTION
With the growing interest in conducting clin-
ical trials in primary Sjögren’s syndrome
(SS), having speciﬁc and valid outcome mea-
sures became a necessity. For that purpose,
an international collaboration was set up to
develop and validate the EULAR Sjögren’s
syndrome disease activity index (ESSDAI)1
and EULAR Sjögren’s syndrome patient
reported index (ESSPRI).2
The ESSDAI is a systemic disease activity
index that was generated in 2009. This score
has been developed by consensus of a large
group of worldwide experts from European
and North American countries, supported
by the EULAR (project code CLI 010).1
It includes 12 domains (ie, organ systems: cuta-
neous, respiratory, renal, articular, muscular,
peripheral nervous system (PNS), central
nervous system (CNS), haematological, glan-
dular, constitutional, lymphadenopathic,
biological). The ESSDAI includes organ-by-
organ deﬁnitions that were agreed on by a
large number of experts. Each domain is
divided into 3–4 levels of activity. Deﬁnition of
each activity level is provided by a detailed
description of what should be considered in
that item. The aim was to obtain a standar-
dised instrument for the homogenous evalu-
ation of systemic activity in order for the
ESSDAI to be used as outcome criteria to
evaluate primary SS in clinical trials as well as
daily practice.
This tool has been validated in a large inde-
pendent cohort and has been shown to have a
high content validity, to be highly reproducible
and to be able to detect change.3 4
In the past few years, the use of this tool has
become more and more prevalent,5–7 particu-
larly in the context of randomised controlled
trials (RCTs).8–10 With the growing use of the
ESSDAI, some domains appeared to be more
challenging to rate than others. In the context
of an RCT, ensuring a more accurate and
reproducible rating of each domain, by provid-
ing a more detailed deﬁnition of each
domain, emerged as an urgent need. The
purpose of the present article is to provide a
user guide for clinicians who use the ESSDAI
to help them to measure disease activity and to
ensure the best accuracy of this measure for its
use in RCTs as well as in clinical practice. For
Key messages
▸ The EULAR Sjögren’s syndrome (SS) disease activ-
ity index (ESSDAI) is a clinical index that measures
disease activity in primary Sjögren’s syndrome.
▸ ESSDAI is validated and used in most clinical
studies and ongoing randomised controlled trials.
▸ This glossary provides detailed definitions of each
item; useful in clinical trials to ensure reliability.
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each of the ESSDAI domains, we will focus on the poten-
tially difﬁcult items.
METHODS
This glossary results from an initiative of the steering com-
mittee of the EULAR Sjögren’s task force collaborative
group (project code CLI 010). This group of 10 physician
experts in SS (HB, SJB, TD, J-EG, XM, MR-C, RS, ET, AT
and CV) and a clinical epidemiologist (PR), has led the
development of the ESSDAI. To develop the ESSDAI, we
also contacted one collaborator of a member of the steer-
ing committee (SC) who has vast experience in the use of
the ESSDAI in the clinical and research setting (PB-Z).
Based on their experience in the use of the ESSDAI,
three members of the SC (SJB, XM and RS) identiﬁed
difﬁculties in rating ESSDAI items. They prepared a
draft for a glossary that aimed to clarify these difﬁcult
ratings. This proposal was submitted to other experts of
the SC. They were asked to suggest any changes they
wanted made. Their suggestions were submitted for the
approval of all the SC members by email. The modiﬁca-
tions were integrated until all members of the SC agreed
on a ﬁnal version.
ESSDAI domains glossary
First, two important points have been emphasised by the
SC to be considered by physicians who use the ESSDAI:
1. The ESSDAI has been developed for patients with
primary SS. Therefore, other differential diagnoses
should be ruled out. When the ESSDAI is used, it
should be with the assurance that the signs and symp-
toms are related to primary SS and not to an under-
lying and/or associated disease. Likewise, patients
with primary SS may have concomitant illnesses that
can mimic SS symptoms and organ involvement,
which should be taken into account.
2. When assessing disease activity of an individual
patient, the physician has to keep in mind that he/
she has to exclude damage features that are irrevers-
ible. Therefore, for each single domain, the long-
lasting ﬁxed features (stable for at least 12 months)
should be scored as 0.
Constitutional domain
The rating of this domain should take into account
the following comments:
Fever and night sweats: The presence of fever (measured
by the patient or the physician using a thermometer)
and night sweats is based on patient responses following
direct questioning ‘Have you had fevers or night sweats
in the past 4 weeks?’
If the fever is regularly (at least twice a week) >38.5°C
or if the night sweats wet the nightclothes, score as mod-
erate activity, else in presence of milder constitutional
symptoms score as low activity.
Symptoms that are thought to be due to causes other
than SS, for example, menopause, concomitant infec-
tion or neoplasia, should be scored as 0.
Weight loss: Weight loss should be recent to be taken
into account (within the past 12 weeks). Where the
weight loss is intentional or due to a concomitant illness,
it should be scored as 0.
Constitutional symptoms related to lymphoma should
be scored in the constitutional domain in addition to
the scoring of lymphoma.
Lymphadenopathy and lymphoma domain
To be clearer, we added ‘and lymphoma’ in the title of
the domain.
The rating of this domain should take in account the
following comments:
Lymphadenopathy or splenomegaly: If there is no signiﬁ-
cant lymph node or splenomegaly at the clinical examin-
ation, no other examination is requested. If there are
some clinical abnormalities, and if an ultrasound or CT
scan has been performed, these data will be used for
scoring, else clinical abnormalities should be used for
scoring.
Lymphadenopathies that are thought to be due to
causes other than SS, for example, to a concomitant
infection, should be scored as 0.
Domain
Activity
level Description
Constitutional
Exclusion of fever of
infectious origin and
voluntary weight loss
No=0 Absence of the following
symptoms
Low=3 Mild or intermittent fever
(37.5−38.5°C)/night sweats
and/or involuntary weight
loss of 5–10% of body
weight
Moderate=6 Severe fever (>38.5°C)/
night sweats and/or
involuntary weight loss of
>10% of body weight
Domain
Activity
level Description
Lymphadenopathy
and lymphoma
Exclusion of
infection
No=0 Absence of the
following features
Low=4 Lymphadenopathy
≥1 cm in any nodal
region or ≥2 cm in
inguinal region
Moderate=8 Lymphadenopathy
≥2 cm in any nodal
region or ≥3 cm in
inguinal region, and/
or splenomegaly
(clinically palpable or
assessed by imaging)
High=12 Current malignant
B-cell proliferative
disorder
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Current B-cell malignant proliferative disorder: B-cell prolif-
erative disorders are based on the WHO classiﬁcation
criteria 2011, including under the item ‘Mature B-cell
neoplasms’ of this classiﬁcation.11
Any B-cell malignant disorder should be taken into
account except if it is in complete remission for more
than 6 months after the end of the treatment (including
consolidation treatment).
Thus, recently diagnosed, currently treated, untreated
smouldering low-grade lymphoma, or previously treated
but not in remission B-cell proliferative disorders,
should be taken into account.
The history of treated lymphoma considered in remis-
sion, monoclonal gammapathy of undetermined signiﬁ-
cance should not be scored.
Multiple myeloma is not to be taken into account.
Glandular domain
The rating of this domain should take into account
the following comments.
The importance of parotid, submandibular or lachry-
mal gland swelling should be assessed by clinical exam-
ination and not by ultrasound. Ultrasound is a very
interesting examination for assessing the structure of the
gland and could be very useful for the diagnosis of SS,
but until now it has not been shown to be reliable for
assessing the size of the glands.
The swelling of submandibular is considered limited
when it is <2 cm and important when it is >2 cm at its
wider diameter.
The swelling of lachrymal glands is considered limited
when it is <1 cm and important when it is >1 cm at its
wider diameter.
In case of gland enlargement due only to lymphoma,
lymphoma will be scored in the ‘Lymphadenopathy and
lymphoma’ domain but not in the glandular domain. If
the gland is enlarged independently from lymphoma, or
if the contralateral gland or other salivary glands are
enlarged, both domains should be scored.
Symptoms that are thought to be due to causes other
than SS, for example, to sarcoidosis, IgG4-related disease,
stones or a concomitant infection, should be scored as 0.
Articular domain
The rating of this domain should take into account
the following comments:
Arthralgia is a symptom characterised by joint pain
without inﬂammatory signs in the joint/s involved. Only
arthralgias of inﬂammatory origin should be scored.
This means a positive response to both the following
questions is required: “Have you got pain in your hands/
wrists/ankles and/or feet in the past 4 weeks? Are you
stiff in the morning for at least 30 minutes?”
The synovitis count should be based on the 28 joint
count used for the DAS28 evaluation in rheumatoid
arthritis.12 It is based on clinical examination by a
medical professional or, if clinical examination is not felt
to be accurate (eg, a patient with generally swollen
hands where a deﬁnitive joint count is not possible), on
US examination.
Arthralgias or synovitis due to other causes, such as
osteoarthritis, infectious, metabolic, rheumatoid arthritis
or other autoimmune diseases should be excluded.
Cutaneous domain
Domain
Activity
level Description
Glandular
Exclusion of
stone or
infection
No=0 Absence of glandular
swelling
Low=2 Small glandular swelling
with enlarged parotid
(≤3 cm), or limited
submandibular (≤2 cm) or
lachrymal swelling
(≤1 cm)
Moderate=4 Major glandular swelling
with enlarged parotid
(>3 cm), or important
submandibular (>2 cm) or
lachrymal swelling (>1 cm)
Domain
Activity
level Description
Articular
Exclusion of
osteoarthritis
No=0 Absence of currently active
articular involvement
Low=2 Arthralgias in hands, wrists,
ankles and feet accompanied
by morning stiffness (>30 min)
Moderate=4 1–5 (of 28 total count)
synovitis
High=6 ≥6 (of 28 total count) synovitis
Domain
Activity
level Description
Cutaneous
Rate as ‘No
activity’ stable
long-lasting
features related
to damage
No=0 Absence of currently
active cutaneous
involvement
Low=3 Erythema multiforma
Moderate=6 Limited cutaneous
vasculitis, including
urticarial vasculitis, or
purpura limited to feet
and ankle, or subacute
cutaneous lupus
High=9 Diffuse cutaneous
vasculitis, including
urticarial vasculitis, or
diffuse purpura, or ulcers
related to vasculitis
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The rating of this domain should take into account
the following comments:
Erythema multiforma: are typical targets, or raised,
oedematous papules distributed acrally; involvement of
mucous membranes is possible.
Subacute cutaneous lupus erythematosus (SCLE) is
characterised by two forms, including papulosquamous
lesions and annular lesions that develop in sun-exposed
areas, including the upper back, shoulders, extensor arms,
neck and upper torso, while the face is usually spared.
Cutaneous vasculitis should include purpura, maculo-
papular rash or urticarial rash. Lesions other than
purpura and supposedly due to vasculitis such as isolated
urticarial or macular rash of vasculitic origin should be
conﬁrmed (by histology and/or the presence of cryoglo-
bulins) at least once in patient history.
Cutaneous vasculitic activity is classiﬁed according to
the cutaneous extension as moderate activity (if limited
to <18% of the body surface area) or high activity (if
extended to ≥18% of the body surface area or if
showing presence of ulcers). The body surface area
involved is evaluated according to ﬁgure 1.
If a skin biopsy has been performed this should be
used. Otherwise, scoring is based on clinical examin-
ation by a medical professional with suitable training
and experience.
Cutaneous rash due to infections, drug reaction or
neoplasia should be excluded. In case of SCLE, under-
lying SLE should be excluded.
Pulmonary domain
The rating of this domain should take into account
the following comments:
A persistent cough is scored if linked to bronchial involve-
ment ascertained by either HRCT (bronchial thickening
or dilation) or pulmonary function tests (PFTs) (obstruct-
ive syndrome) and not due to active infection or tobacco
use. Long-lasting (more than (12 months) persistent but
stable cough more likely due to damage than activity
should be scored as 0. Persistent cough only due to bron-
chial dryness should be scored as 0.
To be more precise and clear we modiﬁed the
wording of the low disease activity level and changed
‘or’ by ‘due to’ bronchial involvement.
Interstitial lung disease, if suspected, should have been
ascertained at least once in the patient history by HRCT
by the presence of mainly ground glass aspect (rather
than honeycombing aspects). HRCT should be repeated
if symptoms, or radiological or lung function test wor-
sening has occurred. For follow-up, classiﬁcation is
made either on lung function test and/or shortness of
breath.
Shortness of breath resulting in slight limitation of
physical activity: patient being comfortable at rest, but
for whom ordinary physical activity results in fatigue, pal-
pitation or dyspnoea, is classiﬁed as NYHA stage II and
is scored as moderate activity. If limitation is more
marked with symptoms present for ordinary activity
and/or at rest (NYHA III or IV), activity is scored as
high.
Shortness of breath due to another cause, such as
tobacco-related chronic bronchitis, cardiac insufﬁciency,
arterial pulmonary embolism or infection) should be
scored as 0. Also, other autoimmune diseases associated
with interstitial lung disease should have been excluded.
Non-evolving long-lasting (more than 12 months)
interstitial lung disease thought to be due to damage
rather than activity should be scored as 0.
Domain
Activity
level Description
Pulmonary
Rate as ‘No
activity’ stable
long-lasting
features
related to
damage, or
respiratory
involvement
not related to
the disease
(tobacco use,
etc)
No=0 Absence of currently active
pulmonary involvement
Low=5 Persistent cough due to
bronchial involvement with no
radiographic abnormalities on
radiography Or radiological or
HRCT evidence of interstitial
lung disease with: no
breathlessness and normal lung
function test
Moderate=10 Moderately active pulmonary
involvement, such as interstitial
lung disease shown by HRCT
with shortness of breath on
exercise (NHYA II) or abnormal
lung function tests restricted to:
70% >DLCO ≥40% or 80%
>FVC≥60%
High=15 Highly active pulmonary
involvement, such as interstitial
lung disease shown by HRCT
with shortness of breath at rest
(NHYA III, IV) or with abnormal
lung function tests: DLCO <40%
or FVC <60%
FVC, forced vital capacity; HRCT, high-resolution CT; NYHA,
New York Heart Association.
Figure 1 Body surface area.
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Renal domain
The rating of this domain should take into account
the following comments:
If a renal biopsy has been carried out, this should be
used to rate activity. If not, then proteinuria, haematuria,
urinary pH and blood tests should be used.
Renal tubular acidosis is deﬁned by the presence of
hyperchloraemia and low serum bicarbonate level both
outside the normal laboratory value.
Renal involvement that is thought to be due to causes
other than SS, for example, nephro-angiosclerosis, dia-
betes, renal involvement associated with endocrine dis-
eases, drugs, viral infections, haematological diseases or
other systemic diseases, should be scored as 0.
Long-lasting (more than 12 months) non-evolving
renal involvement thought to be due to damage rather
than activity should be scored as 0.
Muscular domain
The rating of this domain should take into account
the following comments:
Diagnosis of myositis should be made on the association
of clinical symptoms (muscular pain or weakness) and/or
CK elevation and either muscular involvement conﬁrmed
by needle detection on EMG, by diffuse inﬂammation on
MRI and/or active myositis on biopsy. Therefore, having
one positive examination among EMG, MRI or biopsy is
mandatory, but all are not necessary.
EMG should be performed by an accredited neuro-
physiologist. MRI evidence myositis with diffuse inﬂam-
mation has been added to the deﬁnition of muscular
domain, due to the recognised value of this examination
for that purpose. Muscle biopsy is not mandatory in the
deﬁnition of the activity levels of the domain, but
advised in case of uncertainty on the diagnosis. A new
biopsy is not mandatory in case of recurrence of the
same symptoms with creatine kinase elevation and a pre-
vious biopsy showing inﬂammatory myositis.
Patients having only muscular pain but no muscle
weakness and normal creatine kinase level should be
scored as low activity; active myositis is proven either by
abnormal EMG, MRI or biopsy.
Non-autoimmune causes (infection, statins and other
drugs or toxics, etc) should be excluded. Muscle weak-
ness or involvement that is thought to be due to causes
other than SS, such as ﬁbromyalgia, corticosteroids,
statins or other classiﬁed auto-immune disease should
be scored as 0.
Domain
Activity
level Description
Renal
Rate as ‘No
activity’ stable
long-lasting
features related
to damage and
renal
involvement not
related to the
disease.
If biopsy has
been
performed,
please rate
activity based
on histological
features first
No=0 Absence of currently active
renal involvement with
proteinuria <0.5 g/day, no
haematuria, no leucocyturia,
no acidosis or long-lasting
stable proteinuria due to
damage
Low=5 Evidence of mild active renal
involvement, limited to tubular
acidosis without renal failure
or glomerular involvement
with proteinuria (between 0.5
and 1 g/day) and without
haematuria or renal failure
(GFR ≥60 mL/min)
Moderate=10 Moderately active renal
involvement, such as tubular
acidosis with renal failure
(GFR <60 mL/min) or
glomerular involvement with
proteinuria between 1 and
1.5 g/day and without
haematuria or renal failure
(GFR ≥60 mL/min) or
histological evidence of
extra-membranous
glomerulonephritis or
important interstitial lymphoid
infiltrate
High=15 Highly active renal
involvement, such as
glomerular involvement with
proteinuria >1.5 g/day, or
haematuria or renal failure
(GFR <60 mL/min), or
histological evidence of
proliferative glomerulonephritis
or cryoglobulinemia related
renal involvement
GFR, glomerular filtration rate.
Domain
Activity
level Description
Muscular
Exclusion of
weakness due to
corticosteroids
No=0 Absence of currently
active muscular
involvement
Low=6 Mild active myositis
shown by abnormal
EMG, MRI* or biopsy
with no weakness and
creatine kinase
(N≤CK≤2N)
Moderate=12 Moderately active
myositis proven by
abnormal EMG, MRI* or
biopsy with weakness
(maximal deficit of 4/5),
or elevated creatine
kinase (2N<CK≤4N),
High=18 Highly active myositis
shown by abnormal
EMG, MRI* or biopsy
with weakness (deficit
≤3/5) or elevated
creatine kinase (>4N)
*We decided to add this item not included in the initial version since
the value of this examination for the diagnosis of myositis was not
clear until recently.
EMG, electromyogram.
Seror R, et al. RMD Open 2015;1:e000022. doi:10.1136/rmdopen-2014-000022 5
Connective tissue diseases
UniversitÃƒÂƒÃ‚ÂƒÃƒÂ‚Ã‚ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â  degli Studi di Milano. Protected by copyright.
 o
n
 N
ovem
ber 13, 2019 at
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2014-000022 on 20 February 2015. Downloaded from
 
PNS domain
The rating of this domain should take into account
the following comments:
For all peripheral neuropathy (except cranial nerve
neuropathy and small ﬁbre neuropathy), peripheral
neurological involvement should have been ascertained
by NCS at least once. The diagnosis of patients with per-
ipheral neuropathy requires exhaustive evaluation of
signs and symptoms, followed by conﬁrmation by elec-
trodiagnostic studies, which are useful in establishing
the type of neuropathy and whether it is primarily
demyelinating or axonal.
Some types of neuropathy may require additional diag-
nostic tests:
▸ Proximal demyelinating neuropathy: elevated cere-
brospinal ﬂuid protein level and/or sensory evoked
potentials.
▸ Small ﬁbre neuropathy should have been ascertained
by a cutaneous biopsy, and/or altered or absent
laser-evoked potentials and/or abnormal quantitative
sensory testing to thermal stimuli and/or abnormal
sympathetic sensory testing.
For muscular testing, grade 3/5 means that the patient
holds test position against gravity with no added pressure,
but not against external pressure. If the motor deﬁcit is
grade 3 or less, activity should be scored as high.
Peripheral neuropathy that is thought to be due to
causes other than SS, such as diabetes, or due to meta-
bolic or toxic causes, or that are inherited, should be
scored as 0.
Long-lasting (more than 12 months) non-evolving
neurological involvement thought to be due to damage
rather than activity should be scored as 0.
Central nervous system domain
The rating of this domain should take into account
the following comments:
CNS events (except lymphocytic meningitis) must be
supported by abnormalities on MRI able to explain the
symptoms presented by the patient, and different from
what could be observed in a same age subject, according
to an experienced neuroradiologist or neurologist.
Optic neuritis should be conﬁrmed either by
visual-evoked potentials or MRI. Cerebrovascular events
or white matter lesions that are likely due to atheroscler-
osis or cardiac embolism, infectious disease, or other
autoimmune disease, should be scored as 0.
In case of a certain diagnosis of MS by an experienced
neurologist or fulﬁlment of the 2010 McDonald MS
diagnostic criteria,13 involvement should be considered
as MS and should not be scored in the ESSDAI.
Long-lasting (more than 12 months) non-evolving
neurological involvement thought to be due to damage
rather than activity should be scored as 0.
Domain
Activity
level Description
PNS
Rate as ‘No
activity’ stable
long-lasting
features related
to damage or
PNS
involvement not
related to the
disease
No=0 Absence of currently active
PNS involvement
Low=5 Mild active PNS involvement,
such as pure sensory axonal
polyneuropathy shown by NCS
or trigeminal (V) neuralgia
*Proven small fibre neuropathy
Moderate=10 Moderately active PNS
involvement shown by NCS,
such as axonal sensory–motor
neuropathy with maximal motor
deficit of 4/5, pure sensory
neuropathy with presence of
cryoglobulinemic vasculitis,
ganglionopathy with symptoms
restricted to mild/moderate
ataxia, inflammatory
demyelinating polyneuropathy
(CIDP) with mild functional
impairment (maximal motor
deficit of 4/5 or mild ataxia) Or
cranial nerve involvement of
peripheral origin (except
trigeminal (V) neuralgia)
High=15 Highly active PNS involvement
shown by NCS, such as
axonal sensory–motor
neuropathy with motor deficit
≤3/5, peripheral nerve
involvement due to vasculitis
(mononeuritis multiplex, etc),
severe ataxia due to
ganglionopathy, inflammatory
demyelinating polyneuropathy
(CIDP) with severe functional
impairment: motor deficit ≤3/5
or severe ataxia
*We decided to add this item not included in the initial version since
the link between this entity and SS was not clear until recently.
CIPD, chronic inflammatory demyelinating polyneuropathy; NCS,
nerve conduction study.
Domain
Activity
level Description
CNS
Rate as ‘No
activity’ stable
long-lasting
features related
to damage or
CNS
involvement not
related to the
disease
No=0 Absence of currently active
CNS involvement
Moderate=10 Moderately active CNS
features, such as cranial
nerve involvement of
central origin, optic neuritis
or multiple sclerosis-like
syndrome with symptoms
restricted to pure sensory
impairment or proven
cognitive impairment
High=15 Highly active CNS features,
such as cerebral vasculitis
with cerebrovascular
accident or transient
ischaemic attack, seizures,
transverse myelitis,
lymphocytic meningitis,
multiple sclerosis-like
syndrome with motor deficit
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Haematological domain
The rating of this domain should take into account
the following comments:
Cytopenias that are thought to be due to causes other
than SS should be scored as 0.
▸ Cytopenia due to drug-induced toxicity, viral infec-
tions or haematological disorder other than auto-
immunity or lymphoma;
▸ Anaemia due to iron or vitamin deﬁciency;
▸ Neutropenia of ethnic origin or due to drug asso-
ciated agranulocytosis;
▸ Thrombocytopenia linked to hypersplenism.
Other causes of autoimmune cytopenia should have
been discarded.
Biological domain
The rating of this domain should take into account
the following comments:
If both IgG and gammaglobulin levels are available,
take the highest value and continue to use the same test
in the same patient for longitudinal examination.
A clonal component can be detected by serum electro-
phoresis, serum or urine immunoﬁxation or by an
abnormal ratio of free light chains in the serum.
The biological presence of cryoglobulinemia should
be taken into account even if there is no clinical sign,
even in the case of low cryocrit levels (<1%). Clinical
signs related to cryoglobulinemia should be additionally
scored in each domain.
CONCLUSION
Since its development, the ESSDAI has been frequently
used in primary SS clinical studies. The ESSDAI is now
in use as a gold standard, as the SLEDAI or BILAG is in
lupus,14 15 to measure systemic disease activity in clinical
and biological studies in SS that aim at evaluating new
biomarkers of activity.16–19 It has been shown to correl-
ate with B-cell biomarkers such as β2 microglobulin,
serum free light chains of immunoglobulins,5 20 the
cytokine BAFF6 and to be associated with the risk of
lymphoma.6 21
In addition, ESSDAI has started to be used as an
outcome measure in RCTs in SS, and even as the
primary outcome measure in currently ongoing RCTs.
Recently, the deﬁnition of disease activity levels and
thresholds of minimal clinically important improvement
(MCII) have been recently proposed for that tool: a
moderately active disease being deﬁned as an ESSDAI
≥5 and an MCII as a decrease of at least 3 points.22
These cut-offs have started to be used, respectively,
as entry criteria and primary end points for RCTs
(testing tocilizumab [NCT01782235] or abatacept
[NCT02067910]). In this setting, enhancing the accur-
acy and the reliability of disease activity scoring to cor-
rectly classify patients at study entry but also at ﬁnal
evaluation is a crucial point to determine the efﬁcacy of
the drug under investigation.
Finally, the detailed deﬁnitions given in this paper on
the way to rate each of the ESSDAI domains will be
useful in future RCTs as well as in clinical practice. We
hope it will improve the accuracy of clinical trials data
and help to demonstrate the effectiveness of future treat-
ment in patients with primary SS.
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